Horizon Acquires Viela, Will Develop Inebilizumab for MG Symptoms

Horizon Acquires Viela, Will Develop Inebilizumab for MG Symptoms

284940

Horizon Acquires Viela, Will Develop Inebilizumab for MG Symptoms

In a $3.05 billion deal, Horizon Therapeutics will acquire Viela Bio, the developer of inebilizumab, a potential treatment for autoimmune diseases such as myasthenia gravis (MG), the two companies announced. Horizon plans to advance inebilizumab, already approved for treating another rare autoimmune disease, as a therapy for decreasing disease activity and easing symptoms in MG and other disorders, the companies said in a press release. “Adding Viela’s research and clinical development capabilities along with its deep,…

You must be logged in to read/download the full post.